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FRAX®-based intervention thresholds (ITs) were identi-
fied in Singapore in 2018 [1]. Subsequently, in a sepa-
rate study, the impact of age-dependent ITs was deter-
mined on a population-based sample [2]. The mean-
weighted age-dependent thresholds identified in the
two studies were mostly similar with a minor difference
noted at older ages (e.g. at the age of 75 years, major
osteoporotic fracture (MOF) IT being 24% for the for-
mer study vs 25.7% for the latter). The clinical impact
of these minor differences noted at extremely old ages
is unlikely to be significant and is presumed secondary
to the small methodological differences between the two
studies.
Using the intervention thresholds derived from the first
study, and a previously validated economic model adapted
to the Singaporean context, we had shown that treating
with generic alendronate in post-menopausal Singaporean
women was cost-effective at age-dependent FRAX®-
based major osteoporotic fracture (MOF) ITs only above
the age of 65 years and at hip fracture (HF) ITs only above
the age of 60 years [3]. The corresponding fixed ITs that
were found to be cost-effective at any age over 50 years in
Singapore were 14% and 3.5%, respectively [3]. In that
analysis, we used a very conservative cost-effectiveness
threshold that was less than 1 × Singapore’s GDP per
capita (i.e. 0.7 × GDP). We had also based our analysis
on the assumption that bone densitometry was performed
annually on patients being treated for osteoporosis and that
they had follow-up visits with their health care providers
once yearly after being initiated on treatment.
Performing sensitivity analyses can help to increase
the level of confidence in health economic models. To
test the impact of a more generous and realistic cost-
effectiveness threshold of 1 × GDP (SGD 89,000) (as
recommended by the WHO [4]) and the more realistic
clinical practice scenario of bone density scans and
follow-up visits for osteoporosis care once in 2 years that
is becoming the norm in Singapore, we conducted an
additional sensitivity analysis combining these two pa-
rameters. This sensitivity analysis shows that both age-
dependent FRAX®-based MOF and HF ITs are cost-
effective only in those Singaporean women who are 60
years and over treated with generic alendronate (Table 1).
The corresponding fixed thresholds that are now found to
be cost-effective are MOF and HF probabilities of 9%
and 2%, respectively.
Stakeholders in osteoporosis cannot function in silos, and
communication between clinicians, researchers, and health
care policy makers is vital. These cost-effective osteoporosis
treatment thresholds derived using fracture epidemiology,
health care costs, and clinical practice settings specific to
Singapore will be used for discussions with policy makers at
government level so that clinically useful, economically sup-
ported, and pragmatic management guidance for osteoporosis
can be provided to clinicians in Singapore. The findings from
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our original study and the subsequent sensitivity analysis also
highlight the importance of deriving cost-effective and clini-
cally appropriate intervention thresholds unique to each
country.
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Age-MOF IT Alendronate 
Real World Adherence
Costs (SGD) per QALY gained 
(BMD monitoring and follow-up 
visits yearly and cost effectiveness 
threshold of 0.7 x GDP)
Alendronate 
Real World Adherence
Costs (SGD) per QALY gained 
(BMD monitoring and follow-
up visits once in 2 years and 
cost effectiveness threshold of 1 
x GDP): Sensitivity analysis
50 years-2.86% 392,553 260,905
55 years-4.84% 338,025 219,248
60 years-8.09% 113,431 70,263
65 years-13.01% 57,251 31,881
70 years-18.37% 27,396 12,145
75 years-23.98% 11,745 2,583
80 years-26.07% 10,117 155
85 years-28.39 % 8,922 Cost-saving
Age-HF IT
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55 years-1.16% 162,051 102,333
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70 years-6.79% 22,322 9,039
75 years-9.46% 8,456 Cost-saving
80 years-12.65% 3,858 Cost-saving
85 years-15.74% Cost-saving Cost-saving
Colour code: white, cost-saving; light grey, below cost-effectiveness threshold (SGD 89,000/QALY gained); dark grey, not cost-effective (i.e. above
cost-effectiveness threshold)
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